NanoViricides, Inc. to Present at the Nano and Green Tech 2009 Conference being held in conjunction with ChemShow 2009

All Business Wire news

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the Company’s President, Anil R. Diwan, PhD, has been invited to give a talk at the Nano and Green Tech 2009 Conference on November 18, 2009 (http://www.chemshow.com/includes/nano.pdf). The Conference is being held in conjunction and partnership with Chem Show 2009 (http://www.chemshow.com) at the Javits Convention Center in New York City from Nov 17 through 19, 2009.

Dr. Diwan will be speaking in the session entitled “The Intersection of Nanotechnology and Biology”. He will focus on the nanoviricide™ technology platform, explaining the "Find-Encapsulate-Destroy" antiviral strategy. He will also provide a general overview of the Company’s major product platform including the pan-influenza nanoviricide, FluCide(™), anti-HIV nanoviricide HIVCide™, the nanoviricide eye antiviral drug candidate, and the Herpes cold sores and genital herpes drug candidate.

In addition, Dr. Diwan will discuss the Company’s novel broad-spectrum nanoviricides as a low cost approach against Neglected Tropical Diseases (NTD’s) such as Dengue viruses, Rabies virus, and Rotavirus among others. Although long thought of as a problem of developing countries in tropical climates, many of the NTD’s are moving into the developed world as well. To underscore the importance of having treatments available, it was recently reported that Key West's health officials were urging people to take precautions against dengue fever. This was after survey results showed that 41 percent of local residents tested positive for antibodies associated with the disease. The survey was conducted by researchers from the Centers for Disease Control and Prevention and the Florida Department of Health (http://www.miamiherald.com/news/florida/AP/v-print/story/1332029.html).

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com

Copyright 2009 Business Wire

Back to News Home

MSN Money

Search MSN Money

Message Boards

Site Status